Disclosure statement
NP: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex.
Research funding/clinical trials support: Stemline; Novartis; Abbvie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation.
NJ: Research funding has been provided to the institution from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, and Precision Biosciences for clinical studies in which Nitin Jain is a principal investigator. Nitin Jain has participated in advisory board meeting and received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, and Precision Biosciences.